Medical Device | December 01, 2021
Roche completes acquisition of TIB Molbiol
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
Acute therapies continue to report strong growth compared to chronic ones.
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
Since its inception, the company has either acquired or taken a majority stake in five companies
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Subscribe To Our Newsletter & Stay Updated
